2022
Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
BEREC, Luděk; Martin ŠMÍD; Lenka PŘIBYLOVÁ; Ondřej MÁJEK; Tomáš PAVLÍK et. al.Základní údaje
Originální název
Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
Autoři
BEREC, Luděk (garant); Martin ŠMÍD; Lenka PŘIBYLOVÁ (203 Česká republika, domácí); Ondřej MÁJEK (203 Česká republika, domácí); Tomáš PAVLÍK (203 Česká republika, domácí); Jiří JARKOVSKÝ (203 Česká republika, domácí); Milan ZAJÍČEK; Jakub WEINER; Tamara BARUSOVÁ a Jan TRNKA
Vydání
PLoS ONE, Public Library of Science, 2022, 1932-6203
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30303 Infectious Diseases
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.700
Kód RIV
RIV/00216224:14110/22:00126311
Organizační jednotka
Lékařská fakulta
UT WoS
000844536800079
EID Scopus
2-s2.0-85133679431
Klíčová slova anglicky
COVID 19; SARS CoV 2; Viral vaccines; Vaccines; Czech Republic; Immunity; Vaccination and immunization; Booster doses
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 1. 2023 11:16, Mgr. Marie Novosadová Šípková, DiS.
Anotace
V originále
Studies demonstrating the waning of post-vaccination and post-infection immunity against covid-19 generally analyzed a limited range of vaccines or subsets of populations. Using Czech national health data from the beginning of the covid-19 pandemic till November 20, 2021 we estimated the risks of reinfection, breakthrough infection, hospitalization and death by a Cox regression adjusted for sex, age, vaccine type and vaccination status. Vaccine effectiveness against infection declined from 87% at 0-2 months after the second dose to 53% at 7-8 months for BNT162b2 vaccine, from 90% at 0-2 months to 65% at 7-8 months for mRNA-1273, and from 83% at 0-2 months to 55% at 5-6 months for the ChAdOx1-S. Effectiveness against hospitalization and deaths declined by about 15% and 10%, respectively, during the first 6-8 months. Boosters (third dose) returned the protection to the levels observed shortly after dose 2. In unvaccinated, previously infected individuals the protection against infection declined from 97% after 2 months to 72% at 18 months. Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospitalization and death. Boosting restores the original vaccine effectiveness. Post-infection immunity also decreases over time.